Saturday 17 October 2026
Export SCYX’s income statement to Excel — free account
SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.67
0.24
−6.14%
Follow SCYX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | 0.00 |
P/S ratio |
13.10 | 1.53 | — | 2.34 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(4.40) | 1.72 | — | (3.23) | |
P/B ratio |
1.05 | 0.64 | — | 0.72 | |
Price to Tangible BV |
1.06 | 0.64 | — | 0.72 | |
EV/Sales |
8.96 | 0.84 | — | 0.96 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(0.78) | (3.28) | — | (1.49) | |
EV/FCF |
(0.78) | (3.27) | — | (1.49) | |
Quick Ratio |
4.49 | 7.00 | 3.73 | 9.30 | |
Current Ratio |
5.75 | 7.04 | 3.94 | 9.65 | |
Net Debt/EBITDA |
4.52 | (3.82) | 3.50 | 6.97 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.28 | 0.00 | 0.30 | |
Operating CF/Net income |
1.02 | 1.50 | 0.38 | (2.01) | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
1,632.34% | 24.38% | 0.00% | 1,655.74% | |
Selling, General and Administrative Expense of Revenue |
984.13% | 19.30% | 0.00% | 1,752.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
157.49% | 3.68% | 0.00% | 241.70% | |
Graham Net Nets |
0.89 | 0.97 | — | 1.00 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(66.23%) | (26.88%) | — | (51.35%) | |
Free Cash Flow Yield |
(87.47%) | (16.78%) | — | (27.69%) | |
Revenue per Share |
0.05 | 2.99 | 0.00 | 0.02 | |
Operating CF per Share |
(1.40) | 2.95 | (1.27) | (1.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.40) | 2.95 | (1.27) | (1.26) | |
Cash per Share |
6.09 | 6.43 | 9.32 | 4.58 | |
Shareholders Equity per Share |
5.84 | 7.91 | 6.49 | 5.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.84 | 7.91 | 6.49 | 5.66 | |
Free Cash Flow |
(8.72) | 18.40 | (8.10) | (14.88) | |
Working Capital |
40.23 | 34.64 | 46.79 | 50.41 | |
Net Current Asset Value |
34.05 | 30.72 | 26.37 | 48.20 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
4.21 | 3.40 | 4.95 | 4.72 | |
Average Assets |
75.05 | 74.84 | 72.77 | 67.83 | |
Average Common Equity |
47.48 | 52.23 | 45.92 | 55.70 |
Columns are period end dates